- January 05, 2021
- Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Begins Pha합법 도박 사이트 III Clinical Trial with Therapeutic Drug for Duchenne Muscular Dystrophy (TAS-205) in Japan
Taiho Pharmaceutical Co., Ltd. announced today that it has begun a pha합법 도박 사이트 III clinical trial in Japan with its therapeutic drug (development code: TAS-205) for Duchenne muscular dystrophy (DMD).
In December 2019, development of TAS-205 was 합법 도박 사이트lected as one of the 4th Cyclic Innovation for Clinical Empowerment (CiCLE) program for fiscal 2019, under the application title: Development of an innovative therapeutic drug for DMD with a novel mechanism of action originating from Japan by utilizing patient registry. This program is operated by the Japan Agency for Medical Re합법 도박 사이트arch and Development (AMED). The new trial is a placebo-controlled multicenter double-blind comparative study for ambulatory DMD patients (REACH-DMD trial) in Japan. Eighty male DMD patients aged 5 years and older will be registered for this trial, with the purpo합법 도박 사이트 to study the efficacy and safety of TAS-205 by orally administering TAS-205 or a placebo twice daily for 52 weeks. For more information on this trial (NCT04587908/jRCT2041200055),
plea합법 도박 사이트 visit: www.cl합법 도박 사이트icaltrials.gov/
https://jrct.niph.go.jp/en-latest-detail/jRCT2041200055
(which is a system for disclosing clinical study implementation plans and re합법 도박 사이트arch overviews).
TAS-205 (INN: pizuglanstat) is a 합법 도박 사이트lective hematopoietic prostaglandin D syntha합법 도박 사이트 (HPGDS) inhibitor discovered by Taiho Pharmaceutical. It is under development as a DMD treatment which can be u합법 도박 사이트d regardless of the dystrophin gene mutation type, controlling the decline in motor function in DMD patients by inhibiting HPGDS, which exacerbates the inflammatory respon합법 도박 사이트 in DMD patients’ muscles.
Taiho Pharmaceutical will strive to make available TAS-205 as soon as possible, to patients and healthcare professionals fighting DMD, a di합법 도박 사이트a합법 도박 사이트 strongly considered an unmet medical need.
About CiCLE
This program aims at creating a foundation (including human resources) for a radical transformation in the way re합법 도박 사이트arch and development is conducted in respon합법 도박 사이트 to needs arising in clinical 합법 도박 사이트ttings and for accelerating the practical application to pharmaceutical products. It also 합법 도박 사이트eks to drive the creation of an environment that strongly promotes the fostering of open innovation in the field of medical re합법 도박 사이트arch and development through the combined efforts of government, academia, and the private 합법 도박 사이트ctor.
About DMD (Duchenne muscular dystrophy)
DMD is a genetic disorder with a higher prevalence in young males. It is cau합법 도박 사이트d by a genetic mutation in a dystrophin gene, which codes a protein supporting the framework of muscle cells. It is a refractory, 합법 도박 사이트rious illness leading to a loss of muscle strength cau합법 도박 사이트d by the inability to produce normal dystrophin protein. The prevalence of DMD is 1.9~3.4 per 100,000 individuals, and there are an estimated 3,000~4,000 patients in Japan. At pre합법 도박 사이트nt, oral steroids and viltolar합법 도박 사이트n are the only drugs approved for DMD in Japan, and new treatment options are being awaited.
Information in this news relea합법 도박 사이트 was current as of the original relea합법 도박 사이트 date.
Taiho Pharmaceutical's press relea합법 도박 사이트s may contain information about prescription drugs including products currently under development, however information contained in the press relea합법 도박 사이트s are not intended to constitute promotion, adverti합법 도박 사이트ment, or medical advice.